Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An extension study assessing LUM-201

Trial Profile

An extension study assessing LUM-201

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibutamoren (Primary)
  • Indications Somatotropin deficiency
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms OraGrowtH211
  • Sponsors Lumos Pharma
  • Most Recent Events

    • 10 May 2022 According to an Lumos Pharma media release, the company plan to conduct a interim analyses of data of trial by the end of 2022.
    • 10 May 2022 According to an Lumos Pharma media release, based on a review of preliminary safety and efficacy data from both OraGrowtH trials in progress the FDA has lifted the partial hold and will now permit treatment with LUM-201 beyond twelve months. The company plans to extend the duration of the OraGrowtH212 Trial.
    • 10 May 2022 Status changed from suspended to recruiting, according to an Lumos Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top